Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drug that cuts off a tumor’s blood supply shows promising results when paired with chemotherapy

30.12.2002


An experimental drug designed to cut off a tumor’s blood supply showed promising results in patients with advanced colorectal cancer when paired with standard chemotherapy, according to a UCLA Jonsson Cancer Center study published in the Jan. 1 issue of the Journal of Clinical Oncology.



The results of this and subsequent studies of the experimental drug Avastin could change the way oncologists treat patients with this devastating form of cancer, said Dr. Fairooz Kabbinavar, a Jonsson Cancer Center researcher and first author of the peer-reviewed journal article. The combination of Avastin and chemotherapy proved superior to chemotherapy alone in treating advanced colorectal cancer, Kabbinavar said.

"This is a first-ever randomized trial of a potent anti-angiogenic agent, comparing chemotherapy alone to chemotherapy and Avastin in patients with advanced colorectal cancer," said Kabbinavar, an associate professor of hematology/oncology at UCLA who has studied this drug in the lab and in patients for the last decade. "This study could give us a less toxic and a more effective weapon in our growing arsenal of cancer therapies."


A tumor cannot grow bigger than a pinhead unless it establishes an independent blood supply through a process called angiogenesis to provide itself with oxygen and nutrients. Researchers theorize that by stopping or cutting off the new blood supply, they can starve and, they hope, kill the cancer.

In this study by UCLA’s Jonsson Cancer Center researchers and scientists at four other sites nationwide, the angiogenesis inhibitor Avastin was given with the chemotherapy drugs fluorouracil (5-FU) and leucovorin in a two-pronged attack. Researchers hoped that Avastin -- a monoclonal antibody that targets the Vascular Endothelial Growth Factor, a protein that promotes growth of blood vessels -- would help the chemotherapy work more effectively, and vice-versa, providing a synergistic effect.

Results from laboratory and early-phase studies confirm that the drugs help each other to work better, Kabbinavar said.

Patients in the Phase II study detailed in the journal article who received Avastin with chemotherapy had better response rates and median survival times than did patients who were given chemotherapy alone. In addition, those who received the combination also had a longer time before their cancer progressed and had lower levels of a colon cancer marker in their blood than did patients who received chemotherapy alone, Kabbinavar said.

"The patients who got Avastin and chemotherapy did better in all the parameters we use to measure efficacy," Kabbinavar said. "This is a promising study that provided strong enough results to move on to a large Phase III study involving 1,000 patients."

The Phase III study, also conducted at UCLA’s Jonsson Cancer Center and other sites nationwide, was recently completed. Results are expected sometime next year and should provide researchers with a more definitive answer, Kabbinavar said.

"Our hope and our expectation is that the data will hold true in the larger study as well," Kabbinavar said. "This drug combination may prove to be an important new option for patients with newly diagnosed metastatic colorectal cancer."

Avastin and other angiogenesis inhibitors attack cancer differently than do conventional therapies. Chemotherapy works like a non-specific bomb inside the body, attacking all fast-growing cells and often resulting in debilitating side effects such as nausea, hair loss and a dangerous drop in white and red blood cell counts. Angiogenesis inhibitors fight cancer by preventing or cutting off the blood supply that tumors must have to thrive and spread.

In this Phase II study, 104 patients with untreated, advanced colorectal cancer were given Avastin and chemotherapy or chemotherapy alone. Median survival was increased from about 13 months in patients who received chemotherapy alone to about 21.5 months in patients who were given Avastin and chemotherapy.

Median time to progression, or the time until the cancer grows again after treatment, was increased from 5.2 months in the chemotherapy only group to 9 months in the group receiving Avastin and chemotherapy.

Response rates also were better, with 40 percent of the group getting the combination therapy showing a significant response to the drug, versus 17 percent who responded to the chemotherapy alone.

And patients who received the combination therapy had a 54 percent lower risk of disease progression than did those on chemotherapy alone.

"These preliminary results suggest that Avastin, in combination with 5-FU and leucovorin, increases response rate, prolongs time to progression and prolongs survival," the article states. "These data support further evaluation of the efficacy and safety of Avastin."

Colorectal cancer will strike about 148,000 Americans next year alone, according to the American Cancer Society. More than 56,600 people will die from the disease.

Advanced colorectal cancer is incurable, Kabbinavar said. Most patients die within a year, so it’s vital to find new and better ways to treat this disease.

"It’s important for patients with advanced cancers to talk to their oncologists to see if there are any clinical trials available," he said. "They need to be proactive and seek out all options."

For more information on Jonsson Cancer Center studies, call 888-798-0719.

Kim Irwin | EurekAlert!
Further information:
http://www.cancer.mednet.ucla.edu/
http://www.ucla.edu/

More articles from Health and Medicine:

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

nachricht Stem cell transplants: activating signal paths may protect from graft-versus-host disease
20.04.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

DGIST develops 20 times faster biosensor

24.04.2017 | Physics and Astronomy

Nanoimprinted hyperlens array: Paving the way for practical super-resolution imaging

24.04.2017 | Materials Sciences

Atomic-level motion may drive bacteria's ability to evade immune system defenses

24.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>